XML 52 R19.htm IDEA: XBRL DOCUMENT v2.4.0.8
13. Subsequent Event (Notes)
3 Months Ended
Mar. 31, 2014
Subsequent Events [Abstract]  
Subsequent Events [Text Block]
13.    SUBSEQUENT EVENT

In April 2014, we acquired GnuBIO, Inc. (GnuBIO) for approximately $40 million in cash at the closing date, exclusive of contingent consideration related to the achievement of certain milestones, which per the acquisition agreement could total as much as $70 million. The acquisition will be included in our Clinical Diagnostics segment's results of operations from the acquisition date and will be accounted for as a business combination. The amount of acquisition-related cost was minimal as Bio-Rad primarily represented itself during the acquisition process. The goodwill to be recorded will not be deductible for income tax purposes. We are presently unable to report the fair value assessment of the net assets acquired, as more time is needed to complete the information transfer from the seller and include all information into a valuation of individual assets and liabilities, including the contingent consideration. We believe GnuBIO's innovative DNA workflow is well-suited for the clinical diagnostics sequencing market and will leverage our leadership role in the area of droplet digital PCR.